ICAD חוב כולל להון iCAD, Inc.

The price evolution of iCAD, Inc. (ICAD) reflects a debt load level of 0.01. The business relies on AI solutions for early breast cancer detection, which are deeply integrated into clinic infrastructure. However, legacy licensed products are losing relevance, forcing the firm to transition to a cloud-based format. This process is complicated by fierce competition with hardware vendors and the risk of specialized algorithms becoming obsolete.

This ratio measures the company's degree of dependence on borrowed funds relative to its equity, allowing for an assessment of insolvency risk amid rising interest rates. By analyzing the trend of the total debt-to-equity ratio, an investor can determine whether iCAD, Inc. (ICAD) possesses sufficient resources to develop AI algorithms and modernize hospital software without critical over-leveraging amidst uncertainty regarding insurance payouts.